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Objective: Recently, a novel host-related index, the Host-index (H-index), including
both inflammatory and nutritional markers, has been described and observed to strat-
ify prognosis in patients with squamous cell carcinoma (SCC) of the oral cavity more
accurately than other host-related indexes This study aimed to investigate the prog-
nostic performance of the H-index using pretreatment blood tests in patients receiv-
ing up-front surgery for SCC of the larynx.
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Methods: This retrospective observational study included a multicenter series of con-
secutive patients with SCC of the larynx diagnosed between 1 January 2009 and
31 July 2018, whose pretreatment blood tests were available and included the
parameters necessary for the calculation of neutrophil to lymphocyte ratio (NLR) and
the H-index. Their association with disease-free survival (DFS) and overall survival
(OS) was measured.
Results: A total of 231 patients were eligible for the present analysis (median [range]
age, 68 [37-96] years; 191 [82.7%] men). The median follow-up was 73 months. In
multivariable Cox proportional hazards regression models, increasing age (adjusted
hazard ratio [aHR], 1.07 per year; 95% CI, 1.04-1.09), advanced pT stage (aHR = 1.71
95% CI: 1.07-2.71), and having close or positive surgical margins (aHR = 2.01; 95%
CI: 1.21-3.33) were significantly associated with poor OS. Among blood parameters,
a higher neutrophil count was a strong predictor of both worse DFS (aHR for recur-
rence/death = 2.34; 95% CI: 1.24-4.40) and OS (aHR for death = 2.67; 95% CI: 1.51-
4.71). Among inflammatory blood indexes, while NLR was not significantly associated
with DFS or OS, patients with H-index ≥8.37 showed a higher aHR for both recur-
rence/death (2.82; 95% CI: 1.65-4.79) and death (2.22; 95% CI: 1.26-3.89).
Conclusion: In conclusion, the present study confirms the prognostic value of pre-
treatment H-index, an easily measurable inflammatory and nutritional index, in
patients with SCC of the larynx.
Level of Evidence: III
K E YWORD S
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1 | INTRODUCTION
Despite evidence that host-related factors can significantly influence
outcomes in cancer patients, their use in prognostication is still lim-
ited, with the emphasis being on tumor parameters in clinical practice.
As inflammation and immune surveillance play a pivotal role in
cancer development, several inflammation parameters and indexes
have been investigated as potential markers for prognosis in various
types of cancer. In the context of the tumor microenvironment (TME),
several pro-inflammatory mediators are produced by both the tumor
cells and the stroma. These cytokines recruit inflammatory cells such
as neutrophils, monocytes, and myeloid-derived suppressor cells from
the bloodstream, enriching the inflammatory TME and enhancing cell
proliferation and survival, tumor migration, inhibition of adaptive
immunity, and neo-angiogenesis, thus leading to cancer growth and
progression.1 In several cancers including head and neck squamous
cell carcinoma (HNSCC), raised peripheral neutrophil and monocyte
counts have been associated with a poorer prognosis.2 Conversely, as
they are highly immunogenic, cancer cells can induce efficient anti-
tumor immunity with T lymphocytes playing a crucial role in the host
immune response to cancer: both a high number of tumor infiltrat-
ing3-5 and blood circulating lymphocytes2,6 have been observed to be
associated with better outcome in HNSCC.
Another host-related factor intensively investigated with respect
to its prognostic capability is nutritional status. Several parameters are
used as surrogate markers for nutritional status, with albumin levels
and body mass index (BMI) being the most investigated in oncology. A
number of studies have indicated that hypoalbuminemia is associated
with decreased survival of cancer patients, including HNSCC.7 BMI
has a U-shaped relationship with mortality, with both underweight
and overweight patients having poorer prognoses than those with a
healthy BMI.8 Also, anemia has been consistently found to be an inde-
pendent prognostic factor for poor survival in several solid malignant
tumors9 including HNSCC.8 The development of anemia in cancer is
likely to be multifactorial, deriving from complex interactions between
the immune system, TME, and cancer cells but also as consequence of
malnutrition.10
To combine the above-mentioned measures of inflammation
into composite markers of systemic inflammatory response, sev-
eral indexes have been proposed. Among these, the neutrophil to
lymphocyte ratio (NLR), being relatively low-cost, readily accessi-
ble from a full blood count with differential, and simple to calcu-
late, is the most extensively investigated.11 This ratio was
developed by comparing pro-inflammatory and cancer promoting
immune cells, that is, neutrophils, and anti-inflammatory or cancer
suppressive cells, that is, lymphocytes.12 Recently, an umbrella
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review of systematic reviews and meta-analyses of observational
studies confirmed the strong association between a high NLR and
poor prognosis in cancer patients.11 Interestingly, an inverse cor-
relation was observed between the NLR and the number of
tumor-infiltrating CD8+ T cells in the TME, thus supporting the
theory that the peripheral blood compartment may contribute to
the immune milieu in the TME.13
Very recently, a novel and more complete index, the Host-
index (H-index), including both inflammatory and nutritional
aspects was developed.14 This index was proposed by Valero et al,
and includes two host-factors (neutrophils and monocytes) which
are inversely associated with survival as the numerator, with three
other variables (hemoglobin, albumin, and lymphocytes) associ-
ated with a good outcome as the denominator. The H-index has
been shown to stratify prognosis in a large cohort of patients with
SCC of the oral cavity more accurately than other host-related
indexes.14
This study aimed to investigate the prognostic role of H-index
using pretreatment blood tests in patients receiving up-front surgery
for squamous cell carcinoma (SCC) of the larynx.
2 | METHODS
2.1 | Inclusion criteria
A multicenter retrospective observational study conducted with the
approval of the ethics committee of Treviso/Belluno provinces (Date
March 23th 2020/No. 773/CE Marca) was performed in a cohort
of consecutive chemotherapy- and radiotherapy-naïve patients,
who underwent upfront surgery +/ adjuvant (chemo)radiotherapy
for nonmetastatic SCC of the larynx from 1 January 2009 to 31 July
2018. The study network included General and University Hospi-
tals in North Italy, located in Brescia, Ferrara, Monselice, Padova,
Pavia, Pordenone, Treviso, Trieste, and Verona. Inclusion criteria
were (a) head and neck squamous cell carcinoma (HNSCC) arising
from the larynx; (b) curative upfront surgery as primary treatment
modality; and (c) availability of preoperative blood parameters nec-
essary for the calculation of the NLR and H-index. Patients were
specifically excluded if (a) they were diagnosed with T1 glottic SCC;
(b) they had any coexisting conditions or hematological conditions
that could alter inflammatory parameters; (c) they had previous
malignancy or additional synchronous primary tumors; (d) their pre-
treatment blood test results were not available; and (e) they had
metastatic disease.
2.2 | Participants and data
Medical records were reviewed to collect sociodemographic and
clinical characteristics of enrolled patients. Baseline characteris-
tics, including gender, age, smoking habits, drinking habits, cancer
site, pathological TNM staging (eighth edition), grading, surgical
margins, and extracapsular extension, were retrieved. A margin
was classified as positive if there was invasive cancer present at
the inked edge of the specimen or if cancer was less than 1 mm
TABLE 1 Clinicopathological characteristics of the cohort
Characteristic Finding (N = 231)a






































Radiotherapy alone 74 (32.0%)
Chemoradiotherapy 36 (15.6%)
No 121 (52.4%)
aData are presented as number (percentage) of patients unless otherwise
indicated.
bAccording to the eighth Edition TNM Classification for Head and Neck
Cancer, American Joint Committee on Cancer, 2017.
BOSCOLO-RIZZO ET AL. 731
from the inked edge; close if 1-5 mm; and negative if >5 mm dis-
tant from the inked edge. Blood parameters collected at baseline
included hemoglobin (g/L), neutrophils (103/μL), lymphocytes
(103/μL), monocytes (103/μL), and albumin (g/dL). Patients were
routinely followed-up according to consensus guidelines15 with
endoscopic examination of the upper aero-digestive tract every
1-3 months for the first year, 3-4 months during the second year,
4-6 months during the third year, and every 6 months thereafter.
A chest CT scan was annually performed in patients with history
of smoking ≥20 packs/year. Additional dedicated head and
neck imaging was performed based on clinical features and
local protocol.
2.3 | Inflammatory indexes
Using pretreatment blood parameters, we calculated the NLR [neutro-
phils/lymphocytes] and the H-index ([neutrophils  monocytes]/[lym-
phocyte  hemoglobin  albumin]  100).
2.4 | Statistical analysis
The primary and secondary outcomes were the overall survival
(OS) rate and the disease-free survival (DFS) rate, respectively,
according to different H-index values. Descriptive statistics of patient






P-valueEvents 5 years (%) HR (95% CI)a Events 5 years (%) HR (95% CI)a
Gender
Female 40 14 71.6 1.00 (Reference) 12 78.7 1.00 (Reference)
Male 191 96 52.3 1.45 (0.81-2.60) .216 83 57.6 1.41 (0.75-2.63) .289
Age (years)
<60 33 7 78.8 1.05 (1.03-1.07)b <.001 2 93.9 1.07 (1.04-1.09) b <.001
60-69 99 43 58.7 36 63.3
70-79 73 41 49.8 39 53.6
≥80 26 19 30.8 18 31.9
Smoking habits
Never 17 6 70.6 1.00 (Reference) 6 76.5 1.00 (Reference)
Ever 181 85 54.5 1.53 (0.65-3.61) .331 72 60.1 1.21 (0.51-2.87) .760
Missing 33 19 54.2 1.53 (0.52-4.51) .444 17 57.6 0.97 (0.32-2.95) .956
Drinking habits
Never 98 44 59.7 1.00 (Reference) 36 52.7 1.00 (Reference)
Ever 74 37 48.0 0.98 (0.62-1.55) .932 33 67.6 0.95 (0.58-1.57) .832
Missing 59 29 57.9 0.91 (0.48-1.73) .773 26 61.0 1.08 (0.54-2.16) .838
pT
pT1-T2 81 40 55.2 1.00 (Reference) 32 63.3 1.00 (Reference)
pT3-T4 150 70 55.9 1.31 (0.87-1.99) .189 63 60.2 1.71 (1.07–2.71) .024
pN
pN0-pN1 170 73 59.8 1.00 (Reference) 60 67.2 1.00 (Reference)
pN2-pN3 61 37 44.2 1.08 (0.69-1.68) .741 35 45.5 1.39 (0.87-2.21) .169
Grading
G1 17 5 82.4 1.00 (Reference) 4 82.4 1.00 (Reference)
G2 120 52 58.3 1.47 (0.57-3.80) .431 41 66.9 1.55 (0.53-4.56) .422
G3 68 39 40.2 2.04 (0.77-5.40) .150 37 42.5 2.61 (0.89-7.67) .081
Missing 26 14 64.9 1.64 (0.58-4.62) .351 13 69.2 2.10 (0.67-6.17) .205
Surgical margins
Negative 187 79 61.2 1.00 (Reference) 70 65.8 1.00 (Reference)
Close/positive 44 31 32.2 2.32 (1.47-3.67) <.001 25 42.4 2.01 (1.21–3.33) .007
aEstimated from Cox proportional hazard model, adjusted for gender, age, pT, pN, and surgical margins.
bAge considered as continuous variable.
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demographics and clinical characteristics were reported as frequencies
(proportions) for categorical variables, and median (range max-min) for
continuous variables. OS and DFS were used as the endpoint for sur-
vival analysis. OS was defined as the length of time from treatment to
death from any cause. DFS was defined as the length of time from
treatment to the first evidence of clinical recurrence (loco-regional or
distant) or death from any cause. Median follow up time was based on
the Kaplan-Meier method applied to the censored times reversing the
roles of event status and censored. The associations between age,
gender, smoking, alcohol, pathological tumor (pT) and regional nodal
(pN) stage, and surgical margins, and survival was analyzed using a
univariate Cox proportional hazard regression analysis. The resultant
significant variables were selected as candidate prognostic indicators.
Similarly, we investigated the role of blood parameters (hemoglobin,
lymphocytes, monocytes, neutrophils, and albumin), NLR, and H-index
performing a multivariate Cox regression models adjusted for age,
gender, pT, pN, and surgical margins. Results were reported with Haz-
ard Ratios (HR) and 95% confidence intervals (95%CI). Hemoglobin
level was categorized as low or normal according to gender-specific
clinical cut-offs (ie, <12 g/dL, and ≥16 g/dL in women; <14 g/dL,
≥14 g/dL in men). For lymphocytes, monocytes, neutrophils, albumin,
and NLR, we used the optimal cut-offs of previous studies determined
in similar cohort of HNSCC including laryngeal SCC2,7; where data in
the above studies were unclear, the corresponding author was con-
tacted by e-mail with a request for clarification.
Since there are no previous studies evaluating the prognostic per-
formance of the H-index in laryngeal cancer, in our implementation,
recursive partitioning analysis (package “party” [R 4.0.2]) was used to
identify the threshold values of the H-Index, by taking into account
the censored DFS outcome. These cut-offs were also used to analyze
differences in OS. Furthermore, we evaluated the survival difference
of expression level dichotomized at the cut-off points using log-rank






P-valueEvents 5 years (%) HR (95% CI)a Events 5 years (%) HR (95% CI)a
Hemoglobinb
Normal values 145 56 66.4% 1.00 (Reference) 47 70.6% 1.00 (Reference
Low values 86 54 37.3% 1.80 (1.21-2-68) .004 48 45.5% 1.74 (1.14-2.68) .011
Lymphocytes
>1.18 207 94 58.2% 1.00 (Reference) 82 63.2% 1.00 (Reference)
≤1.18 24 16 30.0% 1.68 (0.96-2.96) .071 13 42.1% 1.50 (0.80-2.82) .205
Monocytes
≤0.58 102 57 59.7% 1.00 (Reference) 39 66.2% 1.00 (Reference)
0.59-1.00 101 43 58.3% 1.02 (0.67-1.56) .918 39 61.8% 1.22 (0.77-1.94) .392
≥1.01 28 28 33.7% 1.86 (1.08-3.21) .026 17 42.9% 2.20 (1.21-3.98) .009
Neutrophils
≤4.80 119 49 62.5% 1.00 (Reference) 43 65.6% 1.00 (Reference)
4.81-7.98 87 43 53.0% 1.21 (0.79-1.85) .389 38 59.4% 1.18 (0.75-1.85) .483
≥7.99 25 18 32.0% 2.67 (1.51–4.71) <.001 14 48.0% 2.34 (1.24-4.40) .008
Albumin
≥4.61 15 4 80.0% 1.00 (Reference) 3 78.8% 1.00 (Reference)
3.76-4.60 144 62 59.9% 2.05 (0.74-5.72) .169 53 64.5% 2.27 (0.70-7.36) .174
≤3.75 72 44 41.9% 2.88 (1.01-8.20) .047 39 51.1% 3.12 (0.95-10.23) .061
NLR
≤1.35 28 10 63.8% 1.00 (Reference) 8 68.6% 1.00 (Reference)
1.36-3.85 154 70 57.9% 0.94 (0.48-1.86) .865 62 62.2% 0.92 (0.43-1.95) .822
≥3.86 49 30 43.3% 1.51 (0.73-3.13) .271 25 53.6% 1.20 (0.53-2.71) .667
H-index
≤3.60 148 57 65.2% 1.00 (Reference) 49 68.6% 1.00 (Reference)
3.61-8.36 53 31 41.8% 1.68 (1.07-2.64) .025 28 50.0% 1.73 (1.07-2.79) .026
≥8.37 30 22 32.7% 2.82 (1.65–4.79) <.001 18 46.2% 2.22 (1.26–3.89) .006
Abbreviations: H-index, host-index; NLR, neutrophil to lymphocyte ratio.
aEstimated from Cox proportional hazard model, adjusted for gender, age, pT, pN, and surgical margins.
bLow values: Hemoglobin <12 g/dL for female and <14 g/dL for male.
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tests and Kaplan-Meier curves. A P-value of .05 was considered signif-
icant. Statistical analysis was performed using R software 4.0.2 (The R
foundation for statistical computing, Vienna, Austria).
3 | RESULTS
3.1 | Population
A total of 231 patients were eligible for the present analysis (median
[range] age, 68 [37-96] years; 191 [82.7%] men). Demographic and
clinical characteristics of the cohort are shown in Table 1. The major-
ity of patients presented with advanced stage laryngeal SCC (n = 170,
73.6%). Negative surgical margins were achieved in 187 patients
(80.9%) and nodal metastasis with extracapsular extension was pre-
sent in 30 cases (13.0%). Adjuvant (chemo)radiotherapy was adminis-
tered to 110 patients (47.6%). During a median follow-up of
73 months (interquartile range: 54-92), 95 patients died; cancer was
the cause of death in 60 (63.2%) of them. Thirty-six patients experi-
enced local recurrence, while 33 patients had regional recurrence and
36 distant metastases, 11 of them concomitantly with local or regional
recurrence. A second primary tumor was diagnosed during follow-up
in 26 patients.
Adjusted hazard ratios (aHR) for DFS and OS according to demo-
graphic and clinical factors are reported in Table 2. In multivariable
Cox proportional hazards regression models, increasing age (aHR,
1.07 per year; 95% CI, 1.04-1.09), advanced pT stage (aHR = 1.71
95% CI: 1.07-2.71), and having close or positive surgical margins
(aHR = 2.01; 95% CI: 1.21-3.33) were significantly associated with
poor OS with age and close or positive surgical margins being signifi-
cantly associated also with poor DFS.
Blood samples were obtained a median inter quartile range (IQR)
of 16 (8-28) days before surgery. Table 3 shows the aHR for both
DFS and OS according to blood parameters and inflammatory indexes.
While a low lymphocyte count showed only a trend toward a worse
DFS, low hemoglobin levels and higher monocyte and neutrophil
counts were significantly associated with both poor DFS and OS. In
particular, a higher neutrophil count was a strong predictor of both
worse DFS (aHR for recurrence/death = 2.34; 95% CI: 1.24-4.40) and
OS (aHR for death = 2.67; 95% CI: 1.51-4.71). The aHR for both DFS
and OS increased with decreasing levels of albumin showing a trend
toward a worse OS and reaching statistical significance for DFS.
Finally, while NLR was not significantly associated with DFS or
with OS, both DFS and OS significantly decreased with increasing H-
index category (Table 3). Patients in the higher H-index category
showed a higher aHR for both recurrence/death (2.82; 95% CI:
1.65-4.79) and death (2.22; 95% CI: 1.26-3.89). Notably, compared to
patients with H-index <3.60, those with H-index ≥8.37 showed a both
worse 5-year OS (46.2% vs 68.6%; P = .001—Figure 1) and DFS
(32.7% vs 65.2% P < 0.001; Figure 2). Finally, a significant difference
in terms of both OS and DFS according to H-index values was
observed both in stage II and stage III-IV patients (Figure 3).
4 | DISCUSSION
This study showed that H-index, a novel prognostic host-related can-
cer index originally investigated in patients with SCC of the oral cav-
ity, is also able to stratify by prognosis in patients surgically treated
for SCC of the larynx. Specifically, a high H-index can identify patients
at higher risk for both worse DFS (aHR = 2.82) and OS (aHR = 2.22).
These results confirm previous findings by Valero et al who first
developed this novel index observing its significant prognostic capa-
bility in a large cohort of patients with SCC of the oral cavity.14 More-
over, H-index was observed to significantly stratified the prognosis
also in the conventional low risk group of stage II patients.
In keeping with the biological role of neutrophils and monocytes
in cancer, both a high count of neutrophils and monocytes were asso-
ciated with worse DFS and OS, thus confirming the observations in
previous studies conducted in cancer patients including those with
F IGURE 1 Overall survival curve for the host index (H-index)
F IGURE 2 Disease-free survival curve for the host index (H-
index)
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HNSCC.2 Monocyte-derived tumor-associated macrophages are
indeed drivers of tumor progression by promoting cancer cell prolifer-
ation and survival, angiogenesis and lympho-angiogenesis.16 Similarly,
by secreting cytokines and chemokines and releasing reactive oxygen
species, neutrophils play an essential role in cancer progression,
including promoting angiogenesis, immunosuppression, and cancer
metastasis.17
In contrast with other reports,2 although patients with a low lym-
phocyte count were more likely to suffer recurrence and death, this
association did not reach a statistical significance in our study.
This may be due to the small number of patients in the high-risk cate-
gory according to the previously reported cut-offs.2 Furthermore,
unlike other types of leukocytes, lymphocytes are a heterogeneous
population of cells that serve diverse functions related to tumorigene-
sis and cancer progression. While most CD4+ T cells, CD8+ T cells,
and natural killer cells have anti-tumoral effects, a subset of CD4+ T
cells known as regulatory T cells (Treg) and characterized by the
expression of the master transcription factor forkhead box protein p3,
suppress anticancer immunity.18 Interestingly, it has been observed
that the prevalence of Treg in the peripheral blood of gastrointestinal
cancer patients is significantly higher than that in healthy volunteers19
and that the proliferation potential of circulating lymphocyte CD8+ T
cells was significantly suppressed compared with healthy controls in
patients with lung cancer.20 Thus, a better characterization of differ-
ent subtypes of circulating lymphocytes may provide more accurate
prognostic information. As a consequence, unlike other studies
reporting an association between a high NLR and poor outcome in
HNSCC2 and laryngeal cancer,21 this ratio was not associated with
outcome in the present series. However, other authors have failed to
identify an association between preoperative NLR and DFS both in
laryngeal22 and oropharyngeal SCC.23 Interestingly, in a series of
patients with HNSCC, it was observed that the prognostic capability
of NLR mostly depended on the number of neutrophils with the lym-
phocytes contributing limitedly.2 In this regard, it should also be
F IGURE 3 A, Overall survival curve for the host index (H-index) in stage II patients; B, disease-free survival curve for the Host Index (H-
index) in stage II patients. C, Overall survival curve for the host index (H-index) in stage III-IV patients; D, disease-free survival curve for the host
index (H-index) in stage III-IV patients. Due to the low number of patients having an H-index ≥8.37, H-index was dichotomized
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considered that use of steroids is more frequent in laryngeal cancer,
to reduce oedema and improve breathing, and possibly associated
with a transient increase in neutrophil count. Unfortunately, in the
current retrospective study, we were not able to consider the impact
of this therapy on neutrophil count.
Lower serum albumin levels were observed to be associated with
worse DFS in the present series, thus confirming previous findings7
and highlighting the importance of preoperative nutritional status and
the potential value of nutrient supplementation.24 Indeed, early nutri-
tional intervention in patients with HNSCC results in a better treat-
ment tolerance and an improved outcome.25 Along with weight loss,
anemia is one of the diagnostic criteria for tumor cachexia.26 Anemia
is known to negatively impact the efficacy of (chemo) radiation in
patients with HNSCC.27,28 Anemia (hemoglobin <12 g/dL for women
and <14 g/dL for men) was significantly associated with both OS and
DFS reduction in the present surgical series. This is consistent with a
previous investigation conducted in a large series of patients with
SCC of the larynx showing that, independently from comorbidities,
anemia has a negative influence on overall survival.8
By incorporating different inflammatory parameters and including
surrogates of nutritional status, that is, albumin and hemoglobin, the
H-Index provides a more comprehensive host-related marker for risk
stratification. Based on routinely collected blood parameters not
requiring any additional expenditure, this index makes it possible to
counterbalance the weight given by the different parameters poten-
tially capable of influencing the prognosis in opposite directions.
The main limitations of this study are the retrospective design
and the small sample size. Furthermore, possible noncancer-related
conditions affecting the variables needed for H-index calculation
could not be accounted for in our study.
In conclusion, although our results need to be interpreted with
caution and should be validated in a larger sample, the present
study supports the prognostic value of pretreatment H-index, an
easily measurable inflammatory and nutritional index, in patients
with SCC of the larynx. As the prognostic stratification capability
of H-index was independent from conventional variables, this
index may help to better identify patients at risk for poor out-
come. This is of paramount importance in patient prognostication
and counseling.
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